文献速递乳腺癌骨软组织肉瘤与黑色素瘤

在临床确诊的Li-Fraumeni综合征家系中验证多原发癌与竞争性癌症结局的风险预测模型

Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data.
PubMed 文献 · J Clin Oncol · 2024-04-03

本研究基于MD Anderson癌症中心遗传咨询门诊收集的124个家系、3297例个体的临床咨询队列数据,验证LFSPRO系列模型对TP53有害突变及多原发癌风险的预测性能。模型预测TP53突变的AUC为0.78(95%CI 0.71-0.85),O/E比为1.66(95%CI 1.53-1.80);预测第二原发癌的AUC为0.70(95%CI 0.58-0.82)。作者认为这些已验证模型表现良好并优于标准临床标准,遗传咨询师使用这些数学模型可能改善风险咨询。

要点

  • 基于临床咨询队列124个家系3297例个体验证LFSPRO模型。
  • 预测TP53有害突变AUC 0.78(95%CI 0.71-0.85),O/E比1.66(95%CI 1.53-1.80)。
  • 预测第二原发癌AUC 0.70(95%CI 0.58-0.82),预测肉瘤、乳腺癌等首发癌AUC 0.70-0.83。

核心结论

  • 使用临床咨询队列,既往验证过的模型表现出良好性能并优于标准临床标准。
  • 作者认为遗传咨询师使用这些已开发的数学模型可能实现更好的风险咨询。

研究设计与样本

  • 研究基于MD Anderson癌症中心遗传咨询师在患者(先证者)进行Li-Fraumeni综合征风险评估时收集的家族史数据。
  • 临床咨询队列包含124个家系共3297例个体,其中单原发癌522例、多原发癌125例。
  • 应用LFSPRO软件套件进行风险预测,采用AUC评估区分度、观察/期望(O/E)比评估校准度。

主要发现

  • 预测TP53有害突变:AUC为0.78(95%CI 0.71-0.85),O/E比为1.66(95%CI 1.53-1.80)。
  • 使用LFSPRO.MPC模型预测第二原发癌发生:AUC为0.70(95%CI 0.58-0.82)。
  • 使用LFSPRO.CS模型预测不同癌症类型作为第一原发癌的发生:肉瘤、乳腺癌或其他癌症合并的AUC在0.70至0.83之间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There exists a barrier between developing and disseminating risk prediction models in clinical settings. We hypothesize that this barrier may be lifted by demonstrating the utility of these models using incomplete data that are collected in real clinical sessions, as compared with the commonly used research cohorts that are meticulously collected. MATERIALS AND METHODS: Genetic counselors (GCs) collect family history when patients (ie, probands) come to MD Anderson Cancer Center for risk assessment of Li-Fraumeni syndrome, a genetic disorder characterized by deleterious germline mutations in the TP53 gene. Our clinical counseling-based (CCB) cohort consists of 3,297 individuals across 124 families (522 cases of single primary cancer and 125 cases of multiple primary cancers). We applied our software suite LFSPRO to make risk predictions and assessed performance in discrimination using AUC and in calibration using observed/expected (O/E) ratio. RESULTS: For prediction of deleterious TP53 mutations, we achieved an AUC of 0.78 (95% CI, 0.71 to 0.85) and an O/E ratio of 1.66 (95% CI, 1.53 to 1.80). Using the LFSPRO.MPC model to predict the onset of the second cancer, we obtained an AUC of 0.70 (95% CI, 0.58 to 0.82). Using the LFSPRO.CS model to predict the onset of different cancer types as the first primary, we achieved AUCs between 0.70 and 0.83 for sarcoma, breast cancer, or other cancers combined. CONCLUSION: We describe a study that fills in the critical gap in knowledge for the utility of risk prediction models. Using a CCB cohort, our previously validated models have demonstrated good performance and outperformed the standard clinical criteria. Our study suggests that better risk counseling may be achieved by GCs using these already-developed mathematical models.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Nguyen NH, Dodd-Eaton EB, Corredor JL, et al. Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data. J Clin Oncol. 2024. PMID: 38569124. doi:10.1200/JCO.23.01926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。